Oral dantrolene reduces myalgia and hyperckemia in a child with RYR1-Related Exertional Myalgia/Rhabdomyolysis

RYR1-related exertional myalgia/rhabdomyolysis (ERM) is an underrecognized condition, which can cause limiting muscle symptoms, and may account for more than one-third of undiagnosed rhabdomyolysis cases. Dantrolene has shown promising results in controlling muscle symptoms in individuals with ERM,...

Descripción completa

Detalles Bibliográficos
Autores: Silva, Elis Vanessa de Lima, Donis, Karina Carvalho, Machado, Fabiana Rita Camara, Medeiros, Leonardo Simão, Aschoff, Carlos Alberto de Moura, Souza, Carolina Fischinger Moura de, Poswar, Fabiano de Oliveira, Saute, Jonas Alex Morales
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:Brasil
Institución:Universidade Federal do Rio Grande do Sul (UFRGS)
Repositorio:Repositório Institucional da UFRGS
Idioma:inglés
OAI Identifier:oai:www.lume.ufrgs.br:10183/288863
Acceso en línea:http://hdl.handle.net/10183/288863
Access Level:acceso abierto
Palabra clave:Dantroleno
Mialgia
Rabdomiólise
Canal de liberação de cálcio do receptor de rianodina
Dantrolene
Malignant hyperthermia
Myalgia
RYR1
Rhabdomyolysis
Descripción
Sumario:RYR1-related exertional myalgia/rhabdomyolysis (ERM) is an underrecognized condition, which can cause limiting muscle symptoms, and may account for more than one-third of undiagnosed rhabdomyolysis cases. Dantrolene has shown promising results in controlling muscle symptoms in individuals with ERM, however, its use in children remains poorly documented. This case report presents the successful treatment of a 5-year-old patient with ERM using oral dantrolene. The patient experienced notable improvements, including a reduction in the frequency and intensity of myalgia episodes, no hospitalizations due to rhabdomyolysis, a substantial decrease in creatine phosphokinase (CPK) levels, and enhanced performance on the 6-minute walk test. The use of dantrolene was well-tolerated, and no significant adverse effects were observed. This report adds to the existing evidence supporting the effectiveness of oral dantrolene in managing ERM, and, to the best of our knowledge, this is the first report of the use of dantrolene in a pediatric patient for controlling anesthesia-independent muscle symptoms.